Earnings ·
Reports Q3 net loss of $7.4M on $18.3M revenue as cash drops to $184.8M
ARCTArcturus Therapeutics Holdings Inc.
Arcturus Therapeutics reported a net loss of $7.4 million, or $0.26 per share, for the quarter ended September 30, 2026, compared to a $13.4 million loss in the prior-year period. Revenue was $18.3 million, driven by a $12.0 million termination payment from CSL Seqirus and remaining deferred revenue, partially offset by lower grant income. Cash and cash equivalents decreased to $184.8 million from $230.9 million at year-end 2025, primarily due to clinical development costs. The company highlighted Phase 2 data for ARCT-810 in OTC deficiency and progress on its LUNAR 2.0 platform, with ARCT-032 enrollment expected to complete by year-end 2026. Arcturus Therapeutics is a messenger RNA medicines company focused on developing liver and respiratory therapeutics.